-
Signature
-
Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
-
Stock symbol
-
NMRA
-
Transactions as of
-
Sep 19, 2023
-
Transactions value $
-
$0
-
Form type
-
4
-
Date filed
-
9/21/2023, 08:30 AM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
NMRA |
Common Stock |
Conversion of derivative security |
|
+3.48M |
+181.81% |
|
5.39M |
Sep 19, 2023 |
F-Prime Capital Partners Life Sciences Fund VII LP |
F1 |
transaction |
NMRA |
Common Stock |
Conversion of derivative security |
|
+85K |
+1.58% |
|
5.47M |
Sep 19, 2023 |
F-Prime Capital Partners Life Sciences Fund VII LP |
F1 |
transaction |
NMRA |
Common Stock |
Conversion of derivative security |
|
+63.7K |
|
|
63.7K |
Sep 19, 2023 |
F-Prime Inc. |
F1 |
transaction |
NMRA |
Common Stock |
Conversion of derivative security |
|
+88.3K |
|
|
88.3K |
Sep 19, 2023 |
FBRI LLC |
F1 |
holding |
NMRA |
Common Stock |
|
|
|
|
|
1.91M |
Sep 19, 2023 |
F-Prime Capital Partners Life Sciences Fund VII LP |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
NMRA |
Series A-2 Preferred Stock |
Conversion of derivative security |
|
-63.7K |
-100% |
|
0 |
Sep 19, 2023 |
Common Stock |
63.7K |
|
F-Prime Inc. |
F1 |
transaction |
NMRA |
Series A-2 Preferred Stock |
Conversion of derivative security |
|
-3.48M |
-100% |
|
0 |
Sep 19, 2023 |
Common Stock |
3.48M |
|
F-Prime Capital Partners Life Sciences Fund VII LP |
F1 |
transaction |
NMRA |
Series B Preferred Stock |
Conversion of derivative security |
|
-85K |
-100% |
|
0 |
Sep 19, 2023 |
Common Stock |
85K |
|
F-Prime Capital Partners Life Sciences Fund VII LP |
F1 |
transaction |
NMRA |
Series A-2 Preferred Stock |
Conversion of derivative security |
|
-88.3K |
-100% |
|
0 |
Sep 19, 2023 |
Common Stock |
88.3K |
|
FBRI LLC |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Fmr Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses:
Remarks:
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: FBRI LLC and F-Prime Inc are wholly-owned subsidiaries of FMR LLC. F-Prime Capital Partners Life Sciences Advisors Fund VII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VII LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.